Kornimate/medical-research-clean huggingface dataset:
development of an ai app to improve compliance in periodontal maintenance patients

Conditions: Periodontal Diseases

Summary: an artificial intelligence platform to develop an app which improves compliance in periodontal treatments

to develop the accuracy of an ai-determined decision-making process for compliance score (cs) assignment, to assess clinical efficacy, and develop patient reported outcomes of ai-facilitated communication / education on a subject's oral health behaviors over successive maintenance visits.

Eligibility criteria:
inclusion criteria: 1. subjects 18 to 75-yrs of age 2. subjects with diagnosis and treatment of generalized and/or localized periodontitis stages i, ii, or iii; grades a-c and or peri-implantitis (generalized mild, moderate, or advanced chronic periodontitis) who are following a periodontal maintenance interval of every three months. 3. subjects are able to provide self-care (oral hygiene) without disabilities requiring assistance with daily oral hygiene measures. 4. subjects will have read, understood and signed an institutional review board (irb) approved informed consent form (icf). 5. subjects must be able and willing to follow study procedures and instructions. exclusion criteria: 1. subjects who do not own or are incapable of interacting with a smart phone or device 2. subjects who are incapable of operating an application on a smart phone or device 3. subjects who are not compliant with periodontal maintenance / recall intervals (based on wilson's classification as any lack of compliance with their recommended maintenance interval- therefore exclude subjects who demonstrate erratic compliance or noncompliance)18 4. subjects who require active periodontal therapy during the study 5. subjects who are on immunosuppressive medications, chemotherapy, or radiation therapy which would adversely affect their periodontal stability. 6. subjects participating in other clinical studies involving therapeutic intervention (either medical or dental). 7. subjects, who in the opinion of the investigator, for any reason other than those listed above, will not be able to complete the study per protocol. - exclusion criteria: -
comparison of core stability and otago exercise on balance and quality of life in patients with stroke

Conditions: Stroke

Summary: core stability and otago exercise program has been proved to be effective in many conditions like muscles strenghing, gait improvement and relieving of pain. hence the aim of present study is to compare the effectivness of core stability and otago exercise on balance and quality of life in patients with stroke.

the otago exercise program (oep), consist of resistance training and balance training exercises. the oep is composed of three domains, namely muscle strengthening, balance training with a progression by increasing ankle cuff weights and number of sets, in association with a walking plan. it is a program that incorporates moderate intensity strength exercises focusing on the lower limbs and balance to be performed for about 30 min at least three times a weekstrength training consisted of flexion and extension exercises of the knee, ankle, and toe joints, as well as hip opening exercises to strengthen the sides of the pelvis. balance training consisted of walking backwards, walking in a figure of eight, heel-toe walking, standing on one leg, walking on the heels, walking on the toes, heel-toe walking backwards, standing up from a sitting position, and walking up stairs.exercises and physical activities could promote balance, flexibility, muscular strength, and walking ability among elderly people.oep three times a week, for 6 months, can improve dynamic balance.core stability exercises for five weeks in addition to conventional physiotherapy five days a week for the same period, improved dynamic sitting balance, standing balance, gait and activities of daily living at the post intervention assessment in subacute post-stroke survivors.

Eligibility criteria:
inclusion criteria: * sub acute stroke(3 to 6 months). * ashworth scale 1 to 3. * patients having cognition level is (26-30) according to moca. * patients having (21 to 42) score according to bbs. exclusion criteria: * fractures. * participants with recurrent stroke. * participants with sever spasticity * orthopedic or other neurological impairment that could influence balance.

Keywords: balance quality of life stroke
evaluation of the efficacy of varenicline on cognition, safety, tolerability and pharmacokinetics in subjects with mild-to-moderate alzheimer's disease

Conditions: Alzheimer's Disease

Summary: 1. assess the efficacy of varenicline, relative to placebo, on a performance based measure of cognition in patients with mild to moderate alzheimer's disease 2. evaluate the effects of varenicline on clinically relevant measures including attention and executive function, behavior, and clinician rated global change. 3. evaluate the safety and tolerability of varenicline, relative to placebo, in patients with mild to moderate alzheimer's disease 4. evaluate the pharmacokinetics of varenicline in patients with mild to moderate alzheimer's disease.


Eligibility criteria:
inclusion criteria: * males or females, age 55-85 * diagnosis of probable alzheimer's disease, consistent with criteria from both: 1) national institute of neurological and communicable disease and stroke and alzheimer's disease and related disorders association (nincds-adrda) and 2) diagnostic and statistical manual of mental disorders (dsm iv) * mini-mental status exam score of 14-26 inclusive * rosen-modified hachinski ischemia score of \< or = 4 exclusion criteria: * diagnosis or history of other dementia or neurodegenerative disorders * diagnosis or history of clinically significant cerebrovascular or cardiovascular disease * subjects with pulmonary disease or evidence of clinically significant pulmonary symptoms

Keywords: efficacy safety pharmacokinetics alzheimer's disease
randomized clinical comparison of the endeavor and the cypher coronary stents in non-selected angina pectoris patients

Conditions: Ischemic Heart Disease

Summary: randomized clinical comparison of the serolimus eluting cypher stent and the zotarolimus eluting endeavor stent.


Eligibility criteria:
inclusion criteria: * all patients treated with one or more drug eluting stents in the coronary arteries at one of the 5 heart centers in denmark can be included in the study. exclusion criteria: * the patient will not participate * the patient participates in other randomized stent studies * expected survival \< 1 year * allergy to aspirin, clopidogrel or ticlopidine * allergy to sirolimus or abt-578
retrospective study on the use of cefaly® device during migraine attacks

Conditions: Migraine

Summary: this is an internet survey to collect data on the use of the cefaly device to treat migraine attacks in regular cefaly users.

about 1000 cefaly users, having the device since more than one year and having reordered electrodes in the last year, will be invited to participate to an internet survey. this survey contains at most 8 questions, and data will be collected completely anonymously. questions concern the use or not of the cefaly during migraine attacks, the number of treated attacks and the number and type of acute anti-migraine drugs that were avoided thanks to the use of the cefaly.

Eligibility criteria:
inclusion criteria: * subjects using cefaly device regularly for more than a year identify by reordering of electrodes during the last year. * history of likely episodic or chronic migraine with or without aura diagnosed by a physician exclusion criteria: * n/a
endourage complete spectrum oral mucosal drops (omd) in adults desiring a reduction in ethanol use

Conditions: Alcohol Drinking; Alcohol Use, Unspecified; Alcohol Abstinence; Alcohol-Related Disorders

Summary: this is the first clinical trial of endourage omd 1200 for persons desiring to reduce their alcohol consumption.

cbd is the second most abundant component of the cannabis plant after tetrahydrocannabinol (thc). unlike thc, cbd does not get users high, but there is some evidence suggesting that it might have anti-anxiety, anticonvulsant, anti-inflammatory and immune boosting, antioxidant effects. currently, the only cbd product approved by the food and drug administration is a prescription oil called epidiolex (greenwich biosciences, inc. 2018). it is approved to treat two types of epilepsy. aside from epidiolex, state laws on the use of cbd vary. while cbd is being studied as a treatment for a wide range of conditions, including parkinson's disease, schizophrenia, diabetes, multiple sclerosis and anxiety, and addiction, research supporting the drug's benefits is still limited. cbd use carries some risks. though it is often well-tolerated, cbd can cause side effects, such as dry mouth, diarrhea, reduced appetite, drowsiness, and fatigue. cbd can also interact with other medications you are taking, such as blood thinners. another cause for concern is the unreliability of the purity and dosage of cbd in products. a recent study of 84 cbd products bought online showed that more than a quarter of the products contained less cbd than labeled. in addition, thc was found in 18 products. if you plan to use products containing cbd, talk to your primary health care provider. people take cannabidiol by mouth for anxiety, bipolar disorder, a muscle disorder called dystonia, seizures, multiple sclerosis, parkinson's disease, and schizophrenia. cannabidiol is possibly safe when taken by mouth and appropriately in adults. cannabidiol doses of up to 300 mg daily have been used safely for up to 6 months. higher doses of 1200-1500 mg daily have been used safely for up to 4 weeks. cannabidiol sprays used under the tongue have been used in doses of 2.5 mg for up to 2 weeks.

Eligibility criteria:
inclusion criteria: 1. age 18 years of age or older who can provide informed consent 2. ability to read and write in the english language and follow study-related procedures 3. ability to have mail/ study drug delivered to an address and/or p.o. box in the recipient's name. 4. if a woman of childbearing age, willing to use a dual method of contraception (barrier and/or hormonal) exclusion criteria: 1. active illicit or non-prescribed drug use 2. concomitant use of benzodiazepines 3. concomitant use of antabuse 4. documented history and active treatment for seizure disorder 5. transaminase elevation 6. hepatitis c infection (currently on therapy and/or any transaminitis elevation) 7. hepatitis b infection (currently on therapy and/or any transaminitis elevation) 8. any form of mental impairment that will/could hinder safe participation in the study 9. pregnancy or breast-feeding
statins and cpap in adipose tissue of osa

Conditions: Sleep Apnea, Obstructive

Summary: this study is aimed at examining the alterations in adipose tissue in obstructive sleep apnea (osa) patients in response to treatment with atorvastatin in continuation with standard treatment with continuous positive airway pressure (cpap).

in recent years the role adipose tissue to the development of cardiometabolic disorders has been increasingly recognized. dysfunctional adipose tissue is an important source for systemic inflammation, angii, and ffa, thus increasing cv risk in obese and aging populations. even though heightened cardiovascular risk in osa patients is acknowledged, adipose tissue from osa patients has not been investigated. cpap is standard therapy for osa, but has shown mixed results for improvement of vascular function, insulin sensitivity, and bp, and does not reduce cv events and mortality, even in patients with established cv disease. hence, eliminating ih alone may not be sufficient to repair preexisting damage; additional adjunct strategies aimed at cellular repair may be required to reduce cardiometabolic burden and cv risk. statins have pleiotropic effects including reducing inflammation, and improving bp. the aim of this study is to examine the longitudinal changes in the cellular and molecular composition of adipose tissue in osa subjects in response to 6 months combination therapy of cpap and atorvastatin. we hypothesize that the combination therapy will reduce adipose tissue cellular damage (p16ink4a+γ-h2ax dual positive cells). also, decreases in adipose tissue cellular damage will be associated with improved cardiometabolic profile. these studies will provide pivotal insights into potential therapeutic strategies which may reduce cardiometabolic burden in osa population.

Eligibility criteria:
inclusion criteria * participated in irb 17-003825 * apnea hypopnea index, ahi/rdi ≥10, or ahi/rdi \>5 with significant nocturnal hypoxemia documented by a fall in oxygen saturation to 90% or below. * women of child-bearing age will be allowed to participate if they agree to use acceptable birth control during the study period. * tsh levels in range of 0.3-6 miu/l (tsh above 6 miu/l will be allowed if free thyroxine (free t4) is within normal range) exclusion criteria * elevated alt (\>3 times upper normal limit) * fasting glucose \>120 mg/dl and/or hba1c ≥ 6.5 % * females planning to be pregnant in next six months will not be included in the study * known serious or hypersensitivity to hmg-coa reductase inhibitors. * alcohol consumption \>3 units/day

Keywords: obstructive sleep apnea adipose tissue
dexmedetomidine and blood coagulation

Conditions: Blood Coagulation Disorder

Summary: dexmedetomidine may alter whole blood coagulation. however, little is known about the dose-response relationships according to the blood concentration of dexmedetomidine. the investigators have therefore performed the present study to measure the effect of dexmedetomidine on the coagulation pathway according to the drug concentration level using a rotational thromboelastometry test.


Eligibility criteria:
inclusion criteria: * healthy volunteers * age: 20 to 65 years * body weight \> 50 kg * volunteers who provided informed consent exclusion criteria: * hematologic disease * anticoagulant medication
neurocognitive changes in patients with remitting relapsing multiple sclerosis treated with natalizumab

Conditions: Multiple Sclerosis; Cognitive Impairment

Summary: cognitive impairment is seen in about half of patients with relapsing remitting ms. our knowledge about long term development of cognitive performance under natalizumab therapy is limited. we want to demonstrate with this study that patients treated with ntz improve in neurocognitive tests over the long term.

impaired cognitive function may represent damage to brain regions that are not involved in physical functions, hence may not be detected during routine neurological assessment. despite the high prevalence of cognitive impairment in ms, cognitive function is not assessed routinely in clinical practice. the perception that cognitive assessments are costly, time-consuming, complicated, and difficult to administer and interpret has contributed, at least in part, to the failure to incorporate cognitive testing into standard clinical evaluation of patients with ms. cognitive impairment may also reduce the ability of patients to comprehend and adhere to treatment concepts (bobholz 2003). early detection of cognitive impairment is important to initiate therapeutic intervention, even though the optimal treatment of cognitive decline in ms is at the moment controversial. preliminary studies suggest an essential role of disease modifying therapies (dmt) in inhibition of cognitive deterioration in patients with ms (barak 2002, flechter 2007). data about long term cognitive performance of multiple sclerosis patients treated with natalizumab is limited. one study demonstrated in ms patients treated with natalizumab an improvement in sdmt (symbol digit modalities test) of 16.4% over a period of 2 years (piehl 2010). sdmt is a screening tool for cognitive impairment in ms patients, mainly measuring working memory and speed processing. as sdmt only covers a part of the neurocognitive impairments seen in ms patients, there is a need for further studies to gain a more complete picture.

Eligibility criteria:
inclusion criteria: * patients between 18 and 55 years at presentation * diagnosis of relapsing-remitting ms according to revised mcdonald criteria 2005 * patients treated with ntz * edss under 5.5 exclusion criteria: * brain pathology other than ms * known history of head trauma * pure spinal manifestation of demyelization * neuromyelitis optica * primary and secondary progressive ms * benzodiazepine intake within the last three months * relapse within the last three months * steroid intake within the last three months * history of severe depressive disorder and/or suicidality, seizure, drug or alcohol abuse * no informed consent * insufficient knowledge of german

Keywords: multiple sclerosis cognitive impairment natalizumab sdmt
a dangerous triad in ageing and in chronic obstructive pulmonary disease (copd) - reduced muscle mass, impaired muscle function and malnutrition

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the investigators have taken part in the development of simple muscle function tests and studied physical training and energy turnover in patients with chronic obstructive pulmonary disease, copd. the investigators have found that muscle wasting in copd is related to poor prognosis and that physical training might lead to improved, less energy-demanding muscle function. elderly subjects also suffer from muscle wasting that leads to frailty, poor autonomy and, secondarily, fractures. in the planned study the investigators will validate simple muscle function tests (hand grip strength, heel rise test, voluntary quadriceps muscle strength, 30 m walking test and balance tests) in both groups by relating them to an involuntary, magnet stimulated, test of quadriceps force, hrql, tests of body composition (impedance, dxa) and recordings of physical activity. the relation between food intake, systemic inflammation, muscle mass and function will be analysed. the study has been ethically approved and started in copd patients and will be expanded to a representative sample of elderly. simple, evaluated muscle function tests applied in primary care may be used for early detection of muscle dysfunction in copd patients and elderly so that early intervention against impaired muscle function can be started. analyses of food intake and of inflammatory markers might identify factors of special importance for muscle dysfunction, which eventually might lead to improved dietary therapy and pharmacological interventions.


Eligibility criteria:
inclusion criteria: * women and men between 65 and 81 years of age, randomly selected from the national registration, are invited to take part in the study. * patients referred to the outpatient clinic of the lung unit at sahlgrenska university hospital with a diagnosis of copd are asked for participation. * inclusion criteria for copd patients: * clinical diagnosis of copd * fev% \< normal value minus 2 sd * smoking history; 10 pack years or more exclusion criteria: * any specific muscular disease * severe disease or handicap making investigations impossible * exclusion criteria for copd patients: * any specific muscular disease * any co-existing serious disease
efficacy, safety, and tolerability study of oral full-spectrum microbiotatm (cp101) in subjects with autism spectrum disorder and associated gi symptoms (sprout)

Conditions: Autism Spectrum Disorder; Autism; ASD; Autistic Thinking; Autistic Behavior; Finch; FMT; Fecal Microbiota Transplant; CP101; SPROUT; Fecal Transplant

Summary: adolescent autism spectrum disorder subjects with associated gi symptoms will be randomized to receive oral dosing of cp101 capsules in treatment group i or matching placebo capsules in treatment group ii. the purpose of this study is to demonstrate the safety and effectiveness of cp101 in subjects with asd and associated gi symptoms.

this is a randomized double-blind placebo controlled study of cp101 (full-spectrum microbiota®) in children with autism spectrum disorder and associated gastrointestinal symptoms

Eligibility criteria:
inclusion criteria: * male or female ages 5 to 17 * diagnosis of asd by health care provider * cars-2 score ≥35 by the study evaluator * 1 year history of chronic abnormal bowel function with/without gi symptoms * gsrs/constipation sub-score ≥3.0, or/and gsrs/diarrhea sub-score ≥3.0, during screening exclusion criteria: * inability to ingest intact capsules. * change or anticipated change of prescription medications and/or nutrition supplement and/or therapy to treat asd symptoms * prior history, evidence, or diagnosis of inflammatory bowel disease or chronic autoimmune gi disease * below 5th percentile for weight on centers for disease control and prevention (cdc) growth chart based on age * history of fecal microbiota transplantation (fmt) for any condition, regardless of route of administration within 12 months of screening, or plan to undergo during the study * history of epilepsy or any other seizure (except febrile seizure) disorder. * enrollment in any other investigational drug or device study within 8 weeks prior to investigational study medication (cp101/placebo) administration or within 5 half-lives of the last dose of the previous investigational compound, whichever is longer. * major intra-abdominal surgery within the past 60 days prior to screening (excluding appendectomy or cholecystectomy) and/or planned invasive surgery/hospitalization during the study. * use of systemic antibiotics, systemic antiviral, or systemic antifungal (non-topical) for any condition during 8 weeks prior to screening, or any anticipated use of above for any condition (e.g., frequent otitis media requiring antibiotics) before eot (week 24). * recent change or anticipated change of non-dietary probiotics. * any clinically significant condition that would jeopardize the safety or rights of the subject, or would confound the results of the study, in the opinion of the principal investigator. * clinically significant laboratory abnormalities at screening at the discretion of the principal investigator. * pregnant, breast-feeding, or positive pregnancy test at screening (for females of child-bearing potential) or for sexually active subjects (as determined by the principal investigator), who refuses to practice an acceptable form of birth control for the duration of the study.
high pain intervention in cesarean sections

Conditions: Other Chronic Postoperative Pain

Summary: in previous studies the investigators have seen that the severity of pain one day after cesarean delivery can predict the presence of pain and depression 2 months later. the investigators believe those at risk for severe acute post-partum pain can be identified, and medical interventions can be tailored to manage postoperative pain more effectively.

this study is randomizing patients into 2 different groups and seeing if by altering our pain management with this group of patients their acute 24 hour evoked pain is less than anticipated; and the incidence of persistent pain and depression when contacted 2 months after delivery is decreased. this study is designed to see if these additional interventions would prove effective for patients at risk of having high pain level after cesarean surgery.

Eligibility criteria:
inclusion criteria: * elective cesarean section * age \>/= 18 years old * not allergic proposed study medications * predicted to experience high pain postop based on preoperative evaluation exclusion criteria: * allergy to study medications * known hepatic disease * weight \> 300 lbs

Keywords: chronic pain post delivery postpartum depression tailored pain management